Boston Pharmaceuticals
Blueprint Therapeutics
Daiichi Sakyo
Eli Lilly
GSK
Helsinn
Ignyta
Inno N
LoxoOncology
Roche
Taiho
Turning Point Therapeutics
Published | Pages | Publisher | Report code |
---|---|---|---|
Mar 2021 | 150 | Kuick Research | ASDR-575416 |
Boston Pharmaceuticals
Blueprint Therapeutics
Daiichi Sakyo
Eli Lilly
GSK
Helsinn
Ignyta
Inno N
LoxoOncology
Roche
Taiho
Turning Point Therapeutics